## KVUE: Kenvue Inc. - XLP: Consumer Defensive

### Executive Summary

VALUE thesis: PEG 0.88 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($16.33)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Orion Porfolio Solutions LLC Purchases 66,112 Shares of Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251216T113625 | Neutral | Relevance: 100%
- Orion Portfolio Solutions LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 30.4%, purchasing an additional 66,112 shares to now hold 283,590 shares valued at $5.94 million. The article also notes significant insider buying from Director Jeffrey C. Smith and highlights analyst ratings, with the stock currently holding an average "Hold" rating and a consensus target price of $20.23. Kenvue offers a quarterly dividend with a yield of approximately 4.8%, but faces a high payout ratio of 110.67%.

**2. Share Offerings Prompt Huge Insider Buying in These 3 Biotechs**
- Source: 24/7 Wall St. | 20251217T134731 | Neutral | Relevance: 74%
- Recent secondary offerings from Immunovant Inc. (IMVT), Kymera Therapeutics Inc. (KYMR), and Wave Life Sciences Ltd. (WVE) have led to significant insider buying from beneficial owners. This article highlights these major insider purchases, along with a notable acquisition in Kenvue Inc. (KVUE), providing details on the buyers, shares bought, and total costs involved, underscoring insider confidence in these biotech firms.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.0%)
- Blackrock Inc.: 7.6% (-1.9%)
- Price (T.Rowe) Assoc: 6.0% (-31.5%)
- State Street Corpora: 6.0% (-0.2%)
- FMR, LLC: 4.7% (-9.3%)

### Key Risks

1. Long-term trend broken: trading 15.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Forward P/E 15.4x stretched relative to 7% growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $32.8B |
| Beta | 0.56 |
| 52W Range | $14.02 - $25.17 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 15.4 |
| Current P/E | 16.6 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.5% to 1.1% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.84x), long-term trend not supportive. RSI neutral at 55. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.07% (CS: 50) | Neutral |
| RSI_14 | 54.7 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 0.845x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $17.09
- **Stop Loss:** $16.33 (4.4% risk)
- **Target:** $18.61 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 937
- **Position Value:** $16,013.33
- **Portfolio %:** 16.01%
- **Risk Dollars:** $712.50
- **Risk Per Trade:** 0.71%
- **Modifiers:** L1 95% | L2 75% | Combined 0.71x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.26 | $0.28 | +5.7% |
| 2025Q2 | $0.28 | $0.29 | +2.2% |
| 2025Q1 | $0.23 | $0.24 | +5.4% |
| 2024Q4 | $0.26 | $0.26 | +1.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*